gms | German Medical Science

27. Deutscher Krebskongress

Deutsche Krebsgesellschaft e. V.

22. - 26.03.2006, Berlin

The ING tumor suppressor genes and their specific role in the pathogenesis of renal cell carcinoma

Meeting Abstract

  • corresponding author presenting/speaker Ekaterina Nichiporuk - Universitätsklinikum, Würzburg, Deutschland
  • Martin Gasser - Universitätsklinikum, Würzburg
  • Felix Hillig - Universitätsklinikum, Würzburg
  • Tatiana Lebedeva - American Red Cross, HLA Laboratory, Boston, USA
  • Jens Lutz - Universitätsklinikum, Klinikum rechts der Isar, München
  • Martin Grimm - Universitätsklinikum, Würzburg
  • Nader Najafian - Brigham and Women's Hospital, Harvard Medical School, Boston, USA
  • Burkhard Kneitz - Universitätsklinikum, Würzburg
  • Arnulf Thiede - Universitätsklinikum, Würzburg
  • Uwe Heemann - Universitätsklinikum, Klinikum rechts der Isar, München
  • Hubertus Riedmiller - Universitätsklinikum, Würzburg
  • Ana Maria Waaga-Gasser - Universitätsklinikum, Würzburg

27. Deutscher Krebskongress. Berlin, 22.-26.03.2006. Düsseldorf, Köln: German Medical Science; 2006. DocPO311

Die elektronische Version dieses Artikels ist vollständig und ist verfügbar unter: http://www.egms.de/de/meetings/dkk2006/06dkk421.shtml

Veröffentlicht: 20. März 2006

© 2006 Nichiporuk et al.
Dieser Artikel ist ein Open Access-Artikel und steht unter den Creative Commons Lizenzbedingungen (http://creativecommons.org/licenses/by-nc-nd/3.0/deed.de). Er darf vervielfältigt, verbreitet und öffentlich zugänglich gemacht werden, vorausgesetzt dass Autor und Quelle genannt werden.


Gliederung

Text

The inhibitor of growth (ING) family of tumor suppressor genes modulates cell cycle checkpoints, apoptosis, and the process of cellular senescence. Thus, it is involved in cell cycle arrest, regulation of gene transcription as well as DNA repair. p33ING1b plays an important role in the pathogenesis of certain carcinomas by a modulation of p53. We analyzed p33ING1b and p29ING4 gene expression together with specific immune responses in patients with clear cell carcinoma of the kidney (n=50) at different tumor stages according to the classification of Robson. Peripheral blood lymphocytes (PBMCs) from patients (Robson stage I-IV) were stimulated with pools of synthetic overlapping peptides of the p33ING1b or p29ING4 sequences encompassing the full length sequence of these two genes. Furthermore, expression of Il-10 and IFN-γ was analyzed (ELISA, ELISPOT). PBMCs, tumor specific cells, and tumor specimens were further characterized (cytospins, FACS, immunohistology, single and double staining, and immunofluorescence). T cells from stage I/II patients expressed higher IL-10 (n=5) than IFN-γ (n=5) levels in response to p29ING4 peptides. However, no peptides were found that induced a Th2 (IL 10, n=5) type response in stage III/IV patients. Interestingly, distinct residues (AA 211-250) induced a Th1 (IFN-γ, n=5) response in the latter patients. Lymphocytes stimulated with p33ING1b peptide pools expressed IFN-γ as well as IL-10, independently from the tumor stage. Remarkably, immunohistochemical staining as well as Real Time PCR analysis revealed higher numbers of CD4/CD8, CD4/CD25, CD4/Foxp3, CD4/CTLA-4, and NK (CD56) cells as well as IL-10, IFN-γ, and Annexin V expression at the tumor site of stage I/II patients than later tumor stages. However, stronger staining and gene expression of p33ING1b and p29ING4 together with a reduced staining and expression of p53 was observed in stage III/IV patients. In order to exert its function as a growth arrest and apoptosis inducing protein, p53 needs to interact with other tumor suppressor genes like the ING gene family. Subsequently, the loss of ING function may be a potential mechanism for the inactivation of p53 function in renal cell carcinoma. The results of this study may provide the basis for immune therapeutical strategies (induction of apoptosis or of a Th1 response using a vaccination protocol in particular with p29ING4 in the early stage of the disease) in renal cell carcinoma.